Log In Get Started
Press Releases May 27, 2026 08:30 AM

Altimmune to Participate in Upcoming Investor Conferences

Altimmune Announces Participation in Key 2026 Healthcare Investor Conferences

By Maya Rios ALT

Altimmune, Inc., a late clinical-stage biopharmaceutical company focused on developing treatments for serious liver diseases, announced management's participation in the 2026 Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. These events provide a platform to discuss their lead drug candidate, pemvidutide, targeting metabolic liver diseases and alcohol-related liver conditions.

Altimmune to Participate in Upcoming Investor Conferences
ALT

Key Points

  • Altimmune will present at two major healthcare investor conferences in June 2026, including fireside chats.
  • The company is developing pemvidutide, a dual-action therapy for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD).
  • Webcasts of the presentations will be available to investors through the company website, enhancing transparency and engagement.

GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in the following upcoming investor conferences:

  • 2026 Jefferies Global Healthcare Conference
    Thursday, June 4, 2026
    Fireside chat at 12:50 p.m. ET
    New York, NY
  • Goldman Sachs 47th Annual Global Healthcare Conference
    Wednesday, June 10, 2026
    Fireside chat at 8:00 a.m. ET
    Miami Beach, FL

A webcast of the fireside chats will be available via the Events section of the Altimmune website.

About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead investigational candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X

Investor Contact:
Luis Sanay, CFA
Vice President, Investor Relations
[email protected]

Media Contact:
Real Chemistry
[email protected]


Risks

  • As a late-stage clinical biopharmaceutical company, Altimmune’s success depends on positive clinical trial results and regulatory approvals, which remain uncertain.
  • Market response to conference presentations can be variable and may not lead to immediate stock price movement.
  • The biopharmaceutical sector faces sector-specific risks including competition, clinical trial challenges, and dependence on a limited number of drug candidates.

More from Press Releases

LiqTech International Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Jun 4, 2026 Correction: Keystone Acquisition Corp. Announces Closing of $287.5 Million Initial Public Offering Including Exercise of Underwriters’ Over-Allotment Option Jun 4, 2026 Verizon declares quarterly dividend on June 4, 2026 Jun 4, 2026 AmperCap Acquisition Company Completes its $125,000,000 Initial Public Offering Jun 4, 2026 Algoma Steel Releases 2025 Sustainability Report Jun 4, 2026